Open Access

Screening of key genes associated with R‑CHOP immunochemotherapy and construction of a prognostic risk model in diffuse large B‑cell lymphoma

  • Authors:
    • Ran Liu
    • Zhi Chen
    • Shujun Wang
    • Gang Zhao
    • Yan Gu
    • Qi Han
    • Baoan Chen
  • View Affiliations

  • Published online on: August 29, 2019     https://doi.org/10.3892/mmr.2019.10627
  • Pages: 3679-3690
  • Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Diffuse large B‑cell lymphoma (DLBCL) is a common subtype of non‑Hodgkin lymphoma, which is curable in the majority of patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R‑CHOP) immunochemotherapy. However, the therapeutic mechanism of R‑CHOP has not been elucidated. The GSE32918 and GSE57611 datasets were retrieved from The Gene Expression Omnibus database. The differentially expressed genes (DEGs) associated with R‑CHOP therapy were identified using limma. Combined with prognostic information in GSE32918, DEGs found to be significantly associated with prognosis were selected using univariate Cox regression analysis and a risk prediction model was constructed. Based on this model, the samples in the training set (GSE32918) were divided into high and low risk score groups according to the median risk score. A total of 801 DEGs were identified between the R‑CHOP treated DLBCL and primary DLBCL samples, from this 116 prognosis‑associated genes were selected. Using Cox proportional hazards model, an optimal combination of 12 genes [including calcium/calmodulin dependent protein kinase I (CAMK1), hippocalcin like 4 (HPCAL4) and ephrin A5 (EFNA5)] was selected, and the sample risk score prediction model was constructed and validated. The DEGs between high risk score and low risk score groups were significantly enriched in functions associated with ‘response to DNA damage stimulus’, and pathways including ‘cytokine‑cytokine receptor interaction’ and ‘cell cycle’. The optimal combination of the 12 genes, including CAMK1, HPCAL4 and EFNA5, was found to be useful in predicting the prognosis of patients with DLBCL after R‑CHOP treatment. Therefore, these genes may be affected by R‑CHOP in DLBCL.

References

1 

Sabattini E, Bacci F, Sagramoso C and Pileri SA: WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: An overview. Pathologica. 102:83–87. 2010.PubMed/NCBI

2 

Dreyling M, Thieblemont C, Gallamini A, Arcaini L, Campo E, Hermine O, Kluin-Nelemans JC, Ladetto M, Le Gouill S, Iannitto E, et al: ESMO Consensus conferences: Guidelines on malignant lymphoma. part 2: Marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol. 24:857–877. 2013. View Article : Google Scholar : PubMed/NCBI

3 

Ganjoo KN, An CS, Robertson MJ, Gordon LI, Sen JA, Weisenbach J, Li S, Weller EA, Orazi A and Horning SJ: Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis. Leuk Lymphoma. 47:998–1005. 2006. View Article : Google Scholar : PubMed/NCBI

4 

Patil Y, Sadhukha T, Ma L and Panyam J: Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J Control Release. 136:21–29. 2009. View Article : Google Scholar : PubMed/NCBI

5 

Cultrera JL and Dalia SM: Diffuse large B-cell lymphoma: Current strategies and future directions. Cancer Control. 19:204–213. 2012. View Article : Google Scholar : PubMed/NCBI

6 

Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 346:2352002. View Article : Google Scholar : PubMed/NCBI

7 

Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, et al: IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 90:2188–2195. 1997.PubMed/NCBI

8 

Mclaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol. 16:2825–2833. 1998. View Article : Google Scholar : PubMed/NCBI

9 

Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA and Horning SJ: Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 24:3121–3127. 2006. View Article : Google Scholar : PubMed/NCBI

10 

National Comprehensive Cancer Network, . NCCN Clinical Practice Guidelines in Oncology. 2003.

11 

Pettengell R, Bosly A, Szucs TD, Jackisch C, Leonard R, Paridaens R, Constenla M and Schwenkglenks M; Impact of Neutropenia in Chemotherapy-European Study Group (INC-EU), : Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: Data from the INC-EU Prospective Observational European Neutropenia Study. Br J Haematol. 144:677–685. 2009. View Article : Google Scholar : PubMed/NCBI

12 

Sehn LH, Scott DW, Chhanabhai M, Berry B, Ruskova A, Berkahn L, Connors JM and Gascoyne RD: Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 29:1452–1457. 2011. View Article : Google Scholar : PubMed/NCBI

13 

Barrans SL, Crouch S, Care MA, Worrillow L, Smith A, Patmore R, Westhead DR, Tooze R, Roman E and Jack AS: Whole genome expression profiling based on paraffin embedded tissue can be used to classify diffuse large B-cell lymphoma and predict clinical outcome. Br J Haematol. 159:441–453. 2012. View Article : Google Scholar : PubMed/NCBI

14 

Scholtysik R, Kreuz M, Hummel M, Rosolowski M, Szczepanowski M, Klapper W, Loeffler M, Trümper L, Siebert R and Küppers R; Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe, : Characterization of genomic imbalances in diffuse large B-cell lymphoma by detailed SNP-chip analysis. Int J Cancer. 136:1033–1042. 2015. View Article : Google Scholar : PubMed/NCBI

15 

Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W and Smyth GK: limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43:e472015. View Article : Google Scholar : PubMed/NCBI

16 

Li S, Sun YN, Zhou YT, Zhang CL, Lu F, Liu J and Shang XM: Screening and identification of microRNA involved in unstable angina using gene-chip analysis. Exp Ther Med. 12:2716–2722. 2016. View Article : Google Scholar : PubMed/NCBI

17 

Parrish RS and Spencer HJ III: Effect of normalization on significance testing for oligonucleotide microarrays. J Biopharm Stat. 14:575–589. 2004. View Article : Google Scholar : PubMed/NCBI

18 

Kaminskyi R, Kunanets N, Pasichnyk V, Rzheuskyi A and Khudyi A: Recovery gaps in experimental data. COLINS. 108–118. 2018.

19 

Bolstad BM, Irizarry RA, Åstrand M and Speed TP: A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 19:185–193. 2003. View Article : Google Scholar : PubMed/NCBI

20 

Szekely GJ and Rizzo ML: Hierarchical clustering via joint between-within distances: Extending Ward's minimum variance method. J Classification. 22:151–183. 2005. View Article : Google Scholar

21 

Press W, Teukolsky S, Vetterling W and Flannery B: Section 16.4. Hierarchical clustering by phylogenetic trees. Numerical recipes: The art of scientific computing. 868–881. 2007.

22 

Wang L, Cao C, Ma Q, Zeng Q, Wang H, Cheng Z, Zhu G, Qi J, Ma H, Nian H and Wang Y: RNA-seq analyses of multiple meristems of soybean: Novel and alternative transcripts, evolutionary and functional implications. BMC Plant Biol. 14:1692014. View Article : Google Scholar : PubMed/NCBI

23 

Wang P, Wang Y, Hang B, Zou X and Mao JH: A novel gene expression-based prognostic scoring system to predict survival in gastric cancer. Oncotarget. 7:55343–55351. 2016.PubMed/NCBI

24 

Huang da W, Sherman BT and Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI

25 

Tibshirani R: THE lasso method for variable selection in the COX model. Stat Med. 16:385–395. 1997. View Article : Google Scholar : PubMed/NCBI

26 

Goeman JJ: L1 penalized estimation in the Cox proportional hazards model. Biom J. 52:70–84. 2010.PubMed/NCBI

27 

Adjei AA and Hidalgo M: Intracellular signal transduction pathway proteins as targets for cancer therapy. J Clin Oncol. 23:5386–5403. 2005. View Article : Google Scholar : PubMed/NCBI

28 

Wang D, Zhang B, Gao H, Ding G, Wu Q, Zhang J, Liao L and Chen H: Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer. BMC Cancer. 14:2512014. View Article : Google Scholar : PubMed/NCBI

29 

Sinha A and Bagga A: Rituximab therapy in nephrotic syndrome: Implications for patients' management. Nat Rev Nephrol. 9:154–169. 2013. View Article : Google Scholar : PubMed/NCBI

30 

Sfikakis P, Souliotis V, Fragiadaki K, Moutsopoulos H, Boletis J and Theofilopoulos A: Increased expression of the Foxp3 functional marker of regulatory t cells following b cell depletion with rituximab in patients with lupus nephritis. Clin Immunol. 123:66–73. 2007. View Article : Google Scholar : PubMed/NCBI

31 

Ishii H, Baffa R, Numata SI, Murakumo Y, Rattan S, Inoue H, Mori M, Fidanza V, Alder H and Croce CM: The FEZ1 gene at chromosome 8p22 encodes a leucine-zipper protein, and its expression is altered in multiple human tumors. Proc Natl Acad Sci USA. 96:3928–3933. 1999. View Article : Google Scholar : PubMed/NCBI

32 

Vecchione A, Ishii H, Shiao YH, Trapasso F, Rugge M, Tamburrino JF, Murakumo Y, Alder H, Croce CM and Baffa R: Fez1/lzts1 alterations in gastric carcinoma. Clin Cancer Res. 7:1546–1552. 2001.PubMed/NCBI

33 

Cabeza-Arvelaiz Y, Sepulveda JL, Lebovitz RM, Thompson TC and Chinault AC: Functional identification of LZTS1 as a candidate prostate tumor suppressor gene on human chromosome 8p22. Oncogene. 20:4169–4179. 2001. View Article : Google Scholar : PubMed/NCBI

34 

Kikuchi M, Katoh H, Waraya M, Tanaka Y, Ishii S, Tanaka T, Nishizawa N, Yokoi K, Minatani N, Ema A, et al: Epigenetic silencing of HOPX contributes to cancer aggressiveness in breast cancer. Cancer Lett. 384:70–78. 2017. View Article : Google Scholar : PubMed/NCBI

35 

Cheung WK, Zhao M, Liu Z, Stevens LE, Cao PD, Fang JE, Westbrook TF and Nguyen DX: Control of alveolar differentiation by the lineage transcription factors GATA6 and HOPX inhibits lung adenocarcinoma metastasis. Cancer Cell. 23:725–738. 2013. View Article : Google Scholar : PubMed/NCBI

36 

Shukla SK, Gunda V, Abrego J, Haridas D, Mishra A, Souchek J, Chaika NV, Yu F, Sasson AR, Lazenby AJ, et al: MUC16-mediated activation of mTOR and c-MYC reprograms pancreatic cancer metabolism. Oncotarget. 6:19118–19131. 2015. View Article : Google Scholar : PubMed/NCBI

37 

Aithal A, Rauth S, Kshirsagar P, Shah A, Lakshmanan I, Junker WM, Jain M, Ponnusamy MP and Batra SK: MUC16 as a novel target for cancer therapy. Expert Opin Ther Targets. 22:675–686. 2018. View Article : Google Scholar : PubMed/NCBI

38 

Downward J: Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 3:11–22. 2003. View Article : Google Scholar : PubMed/NCBI

39 

Slack C, Alic N, Foley A, Cabecinha M, Hoddinott MP and Partridge L: The Ras-Erk-ETS-signaling pathway is a drug target for longevity. Cell. 162:72–83. 2015. View Article : Google Scholar : PubMed/NCBI

40 

Huang Y, Zhang J, Hou L, Wang G, Liu H, Zhang R, Chen X and Zhu J: LncRNA AK023391 promotes tumorigenesis and invasion of gastric cancer through activation of the PI3K/Akt signaling pathway. J Exp Clin Cancer Res. 36:1942017. View Article : Google Scholar : PubMed/NCBI

41 

Martini M, De Santis M, Braccini L, Gulluni F and Hirsch E: PI3K/AKT signaling pathway and cancer: An updated review. Ann Med. 46:372–383. 2014. View Article : Google Scholar : PubMed/NCBI

42 

Mayer IA and Arteaga CL: The PI3K/AKT pathway as a target for cancer treatment. Annu Rev Med. 67:11–28. 2015. View Article : Google Scholar : PubMed/NCBI

43 

Nakamaki T, Baba Y, Abe M, Murai S, Watanuki M, Kabasawa N, Yanagisawa K, Hattori N, Kawaguchi Y, Arai N, et al: Rituximab-induced CD20-mediated signals and suppression of PI3K-AKT pathway cooperates to inhibit B-cell lymphoma growth by down-regulation of Myc. Blood. 128:53122016.

44 

Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa S, Kitamura Y, Yoshida N, Kikutani H and Kishimoto T: Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature. 382:635–638. 1996. View Article : Google Scholar : PubMed/NCBI

45 

Zhu Q, Peng J, Qin H and Yu W: The role of CXC chemokines and their receptors in the progression and treatment of tumors. J Mol Histol. 43:699–713. 2012. View Article : Google Scholar : PubMed/NCBI

46 

Hunninghake GM, Chu JH, Sharma SS, Cho MH, Himes BE, Rogers AJ, Murphy A, Carey VJ and Raby BA: The CD4+ T-cell transcriptome and serum IgE in asthma: IL17RB and the role of sex. BMC Pulm Med. 11:172011. View Article : Google Scholar : PubMed/NCBI

47 

Husson H, Carideo EG, Cardoso AA, Lugli SM, Neuberg D, Munoz O, de Leval L, Schultze J and Freedman AS: MCP-1 modulates chemotaxis by follicular lymphoma cells. Br J Haematol. 115:554–562. 2001. View Article : Google Scholar : PubMed/NCBI

48 

Alinejad V, Dolati S, Motallebnezhad M and Yousefi M: The role of IL17B-IL17RB signaling pathway in breast cancer. Biomed Pharmacother. 88:795–803. 2017. View Article : Google Scholar : PubMed/NCBI

49 

Sharma S, Rajaram S, Sharma T, Goel N, Agarwal S and Banerjee BD: Role of BRCA1 and BRCA2 gene mutations in epithelial ovarian cancer in Indian population: A pilot study. Int J Biochem Mol Biol. 5:1–10. 2014.PubMed/NCBI

50 

Furuta S, Jeng YM, Zhou L, Huang L, Kuhn I, Bissell MJ and Lee WH: IL-25 causes apoptosis of IL-25R-expressing breast cancer cells without toxicity to nonmalignant cells. Sci Transl Med. 3:78ra312011. View Article : Google Scholar : PubMed/NCBI

51 

Pievani A, Belussi C, Klein C, Rambaldi A, Golay J and Introna M: Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies. Blood. 117:510–518. 2011. View Article : Google Scholar : PubMed/NCBI

52 

Venugopal P, Sivaraman S, Huang X, Nayini J, Gregory S and Preisler H: Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia. Leuk Res. 24:411–415. 2000. View Article : Google Scholar : PubMed/NCBI

53 

Wang X, Yang L, Huang F, Zhang Q, Liu S, Ma L and You Z: Inflammatory cytokines IL-17 and TNF-α up-regulate PD-L1 expression in human prostate and colon cancer cells. Immunol Lett. 184:7–14. 2017. View Article : Google Scholar : PubMed/NCBI

54 

Herberich SE, Klose R, Moll I, Yang WJ, Wüstehube-Lausch J and Fischer A: ANKS1B interacts with the cerebral cavernous malformation protein-1 and controls endothelial permeability but not sprouting angiogenesis. PLoS One. 10:e01453042015. View Article : Google Scholar : PubMed/NCBI

55 

Fu X, McGrath S, Pasillas M, Nakazawa S and Kamps MP: EB-1, a tyrosine kinase signal transduction gene, is transcriptionally activated in the t (1;19) subset of pre-B ALL, which express oncoprotein E2a-Pbx1. Oncogene. 18:4920–4929. 1999. View Article : Google Scholar : PubMed/NCBI

56 

Evan GI and Vousden KH: Proliferation, cell cycle and apoptosis in cancer. Nature. 411:342–348. 2001. View Article : Google Scholar : PubMed/NCBI

57 

Eckel-Passow JE, Serie DJ, Bot BM, Joseph RW, Cheville JC and Parker AS: ANKS1B is a smoking-related molecular alteration in clear cell renal cell carcinoma. BMC Urol. 14:142014. View Article : Google Scholar : PubMed/NCBI

58 

Satoh T and Hosokawa M: Structure, function and regulation of carboxylesterases. Chem Biol Interact. 162:195–211. 2006. View Article : Google Scholar : PubMed/NCBI

59 

Redinbo MR and Potter PM: Mammalian carboxylesterases: From drug targets to protein therapeutics. Drug Discov Today. 10:313–325. 2005. View Article : Google Scholar : PubMed/NCBI

60 

Pratt SE, Durland-Busbice S, Shepard RL, Heinz-Taheny K, Iversen PW and Dantzig AH: Human carboxylesterase-2 hydrolyzes the prodrug of gemcitabine (LY2334737) and confers prodrug sensitivity to cancer cells. Clin Cancer Res. 19:1159–1168. 2013. View Article : Google Scholar : PubMed/NCBI

61 

Anikster Y, Haack TB, Vilboux T, Pode-Shakked B, Thöny B, Shen N, Guarani V, Meissner T, Mayatepek E, Trefz FK, et al: Biallelic mutations in DNAJC12 cause hyperphenylalaninemia, dystonia, and intellectual disability. Am J Hum Genet. 100:257–266. 2017. View Article : Google Scholar : PubMed/NCBI

62 

Jung-KC K, Himmelreich N, Prestegård KS, Shi TS, Scherer T, Ying M, Jorge-Finnigan A, Thöny B, Blau N and Martinez A: Phenylalanine hydroxylase variants interact with the co-chaperone DNAJC12. Hum Mutat. 40:483–494. 2019. View Article : Google Scholar : PubMed/NCBI

63 

He HL, Lee YE, Chen HP, Hsing CH, Chang IW, Shiue YL, Lee SW, Hsu CT, Lin LC, Wu TF and Li CF: Overexpression of DNAJC12 predicts poor response to neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer. Exp Mol Pathol. 98:338–345. 2015. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

October 2019
Volume 20 Issue 4

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Liu, R., Chen, Z., Wang, S., Zhao, G., Gu, Y., Han, Q., & Chen, B. (2019). Screening of key genes associated with R‑CHOP immunochemotherapy and construction of a prognostic risk model in diffuse large B‑cell lymphoma. Molecular Medicine Reports, 20, 3679-3690. https://doi.org/10.3892/mmr.2019.10627
MLA
Liu, R., Chen, Z., Wang, S., Zhao, G., Gu, Y., Han, Q., Chen, B."Screening of key genes associated with R‑CHOP immunochemotherapy and construction of a prognostic risk model in diffuse large B‑cell lymphoma". Molecular Medicine Reports 20.4 (2019): 3679-3690.
Chicago
Liu, R., Chen, Z., Wang, S., Zhao, G., Gu, Y., Han, Q., Chen, B."Screening of key genes associated with R‑CHOP immunochemotherapy and construction of a prognostic risk model in diffuse large B‑cell lymphoma". Molecular Medicine Reports 20, no. 4 (2019): 3679-3690. https://doi.org/10.3892/mmr.2019.10627